| Dr Riad R Dali Ahmad, MD | |
|
600 Health Park Blvd, Ste H, Grand Blanc, MI 48439-2558 | |
| (810) 606-7125 | |
| (810) 606-1620 |
| Full Name | Dr Riad R Dali Ahmad |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 37 Years |
| Location | 600 Health Park Blvd, Grand Blanc, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124130539 | NPI | - | NPPES |
| 4703466 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 4301068100 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Genesys Regional Medical Center - Health Park | Grand blanc, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Health Park Medical Practice Pc | 1254698699 | 3 |
News Archive
Bladder cancer is the seventh leading cancer affecting men worldwide and in the United States, it is the fourth leading cancer. Each year, about 350,000 cases are being detected worldwide, and the disease claims 165,000 lives every year.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.
Gannett announced today the launch of a major company-wide, cross-divisional campaign for the National Breast Cancer Foundation. The National Breast Cancer Foundation, Inc., a charitable non-profit organization based in Frisco, Texas, launched the campaign on the first day of National Breast Cancer Awareness month in an effort to promote its Early Detection Program. NBCF's mission is to save lives by increasing awareness of breast cancer through education and by providing mammograms for those in need.
Affymetrix, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children's developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.
› Verified 1 days ago
| Entity Name | Ascension Genesys Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528283033 PECOS PAC ID: 2062323033 Enrollment ID: O20031208000842 |
News Archive
Bladder cancer is the seventh leading cancer affecting men worldwide and in the United States, it is the fourth leading cancer. Each year, about 350,000 cases are being detected worldwide, and the disease claims 165,000 lives every year.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.
Gannett announced today the launch of a major company-wide, cross-divisional campaign for the National Breast Cancer Foundation. The National Breast Cancer Foundation, Inc., a charitable non-profit organization based in Frisco, Texas, launched the campaign on the first day of National Breast Cancer Awareness month in an effort to promote its Early Detection Program. NBCF's mission is to save lives by increasing awareness of breast cancer through education and by providing mammograms for those in need.
Affymetrix, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children's developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.
› Verified 1 days ago
| Entity Name | Health Park Medical Practice Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760901003 PECOS PAC ID: 1254698699 Enrollment ID: O20171120002963 |
News Archive
Bladder cancer is the seventh leading cancer affecting men worldwide and in the United States, it is the fourth leading cancer. Each year, about 350,000 cases are being detected worldwide, and the disease claims 165,000 lives every year.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.
Gannett announced today the launch of a major company-wide, cross-divisional campaign for the National Breast Cancer Foundation. The National Breast Cancer Foundation, Inc., a charitable non-profit organization based in Frisco, Texas, launched the campaign on the first day of National Breast Cancer Awareness month in an effort to promote its Early Detection Program. NBCF's mission is to save lives by increasing awareness of breast cancer through education and by providing mammograms for those in need.
Affymetrix, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children's developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Riad R Dali Ahmad, MD 600 Health Park Blvd, Ste H, Grand Blanc, MI 48439-2558 Ph: (810) 606-7125 | Dr Riad R Dali Ahmad, MD 600 Health Park Blvd, Ste H, Grand Blanc, MI 48439-2558 Ph: (810) 606-7125 |
News Archive
Bladder cancer is the seventh leading cancer affecting men worldwide and in the United States, it is the fourth leading cancer. Each year, about 350,000 cases are being detected worldwide, and the disease claims 165,000 lives every year.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.
Gannett announced today the launch of a major company-wide, cross-divisional campaign for the National Breast Cancer Foundation. The National Breast Cancer Foundation, Inc., a charitable non-profit organization based in Frisco, Texas, launched the campaign on the first day of National Breast Cancer Awareness month in an effort to promote its Early Detection Program. NBCF's mission is to save lives by increasing awareness of breast cancer through education and by providing mammograms for those in need.
Affymetrix, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children's developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.
› Verified 1 days ago
Dr. Indira Alluru, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 414 Perry Rd, Grand Blanc, MI 48439 Phone: 810-695-1849 Fax: 810-695-1736 | |
Isabella Martyna Chojnacki, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-5000 | |
Garret Eugene Clark, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-5986 | |
Ziauddin Syed, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-5981 Fax: 810-606-5990 | |
Dr. Daniel Ramirez, DO Infectious Disease Medicare: Medicare Enrolled Practice Location: 1 Genesys Parkway, Medical Education Suite 4626, Grand Blanc, MI 48439 Phone: 810-606-5986 Fax: 810-606-5589 | |
Sherehan Ibrahim, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-5000 | |
Paul Lafia, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 3399 Pollock Rd, Grand Blanc, MI 48439 Phone: 810-603-0170 Fax: 810-579-1705 |